BioCentury
ARTICLE | Company News

Inspire, Faes deal

June 25, 2007 7:00 AM UTC

FAE and ISPH amended a 2006 deal that granted ISPH exclusive U.S. and Canadian rights to commercialize and develop oral bilastine to treat allergic rhinitis (see BioCentury, Nov. 6, 2006). FAE is now...